Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Buhl, Roland; Solèr, Markus; Matz, Jonathan; Townley, Robert G.; O’Brien, John S.; Noga, Oliver; Champain, K; Fox, Howard; Thirlwell, J.; Cioppa, Giovanni Della

doi:10.1183/09031936.02.00278102

Cited by 165 publications

(157 citation statements)

References 17 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…However, this therapy is not sufficient to reach asthma control in patients with severe refractory asthma [2]. For these patients, there are only a few effective therapeutic options available, including systemic corticosteroids, which have serious adverse effects [3], and monoclonal antibodies against immunoglobulin (Ig)E, which are indicated only for patients with allergic asthma [4]. For nonatopic patients with severe asthma, however, there is an urgent need for better therapies [5].…”

mentioning

confidence: 99%

High-altitude treatment in atopic and nonatopic patients with severe asthma

et al. 2012

View full text Add to dashboard Cite

The beneficial effects of high-altitude treatment in asthma have been attributed to allergen avoidance. Recent evidence shows that this treatment also improves airway inflammation in nonallergic patients. We hypothesised that high-altitude treatment is clinically equally effective in patients with severe refractory asthma, with or without allergic sensitisation.In a prospective observational cohort study, 137 adults with severe refractory asthma (92 with allergic sensitisation), referred for high-altitude (1,600 m) treatment in Davos, Switzerland, were consecutively included. We measured asthma control (Asthma Control Questionnaire (ACQ)), asthma-related quality of life (Asthma-Related Quality of Life Questionnaire (AQLQ)), sino-nasal symptoms (Sino-Nasal Outcome Test (SNOT-20)), medication requirement, postbronchodilator (post-BD) forced expiratory volume in 1 s (FEV1), 6-min walking distance (6MWD), total immunoglobulin (Ig)E, blood eosinophils and exhaled nitric oxide fraction (FeNO) at admission and after 12 weeks.Sensitised and nonsensitised patients showed similar improvements in ACQ (-1.4 and -1.5, respectively; p50.79), AQLQ (1.6 and 1.5, respectively; p50.94), SNOT-20 (-0.7 and -0.5, respectively; p50.18), post-BD FEV1 (6.1% and 5.8% pred, respectively; p50.87), 6MWD (+125 m and +147 m, respectively; p50.43) and oral steroids (40% versus 44%, respectively; p50.51). Sensitised patients showed a larger decrease in total IgE, blood eosinophils and FeNO.High-altitude treatment improves clinical and functional parameters, and decreases oral corticosteroid requirement in patients with severe refractory asthma, irrespective of allergic sensitisation.

show abstract

mentioning

confidence: 99%

High-altitude treatment in atopic and nonatopic patients with severe asthma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Additional evidence suggests that omalizumab decreases the incidence of clinic visits for asthma exacerbations, emergency department (ED) visits, and hospitalizations. 2,[4][5][6][7][8][9] Omalizumab is more expensive than any other medication for asthma. Current US wholesale prices for omalizumab average almost $1300 per patient-month for an asthmatic patient who weighs less than 90 kg.…”

mentioning

confidence: 99%

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

Paltiel

Kuntz³

et al. 2007

Journal of Allergy and Clinical Immunology

103

View full text Add to dashboard Cite

show abstract

“…7 The re are seven ran do mi zed stu di es com pa ring oma li zu mab tre at ment with pla ce bo in ado les cents (≥12 y.o age) and adult pa ti ents. [8][9][10][11][12][13][14] Im pro ve ment in qu a lity of li fe and re duc ti on in emer gency de partment vi sits and hos pi ta li za ti on ra tes we re the common re sults of the se stu di es when com pa red with the con trol gro ups. 15 Furt her mo re, in two of the se seven stu di es in ha led cor ti cos te ro id do ses co uld be re du ced sig ni fi cantly.…”

Section: Discussionmentioning

confidence: 99%

First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report

Arga¹,

Bakırtaş²,

Türktaş³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

1764evere asthma continues to be a significant morbidity and mortality problem despite treatment according to international asthma guidelines.1 Humanized monoclonal anti-IgE antibody (omalizumab) is recently recommended at the fifth step of international asthma guidelines for the treatment of patients older than 12 years of age who have severe persistent allergic asthma uncontrolled despite treatment with high-dose inhaled corticosteroid (>800 µgr/day) in combination with a long-acting β2-agonist and oral leukotriene receptor antagonist and have serum total Ig E between 30-700 IU/ml. 2,3 In this article, we present our clinical experience with omalizumab in the first Turkish child case with severe persistent allergic asthma.First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report A AB BS S T TR RA AC CT T Hu ma n mo noc lo nal an ti-IgE an ti body (oma li zu mab) is re cently re com men ded at the fifth step of in ter na ti o nal ast hma gu i de li nes for the tre at ment of pa ti ents ol der than 12 ye ars of age who ha ve se ve re per sis tent al ler gic ast hma un con trol led des pi te tre at ment with high-do se in ha led cor ti cos te ro id (>800 µgr/day) in com bi na ti on with a long-ac ting β2-ago nist and oral le u kot ri e ne recep tor an ta go nist and ha ve se rum to tal Ig E bet we en 30-700 IU/ml. We star ted oma li zu mab as addon tre at ment to a se ve re per sis tent ast hma tic ca se who had two se ve re ast hma at tacks in the last thre e-month pe ri od, one of which was comp li ca ted with pne u mo me di as ti ni um. This is the first expe ri en ce with oma li zu mab in a child with se ve re ast hma re por ted from our co untry. The first se venmonth of oma li zu mab tre at ment re sul ted in sig ni fi cant im pro ve ments in qu a lity of li fe and pul mo nary func ti ons as well as re duc ti ons in in ha led cor ti cos te ro id do se and da ily symptom sco res.K Ke ey y W Wo or rd ds s: : Ast hma; child; oma li zu mab Ö ÖZ ZE ET T Son yıl lar da, bir in san mo nok lo nal an ti IgE an ti ko ru olan oma li zu mab, ulus la ra ra sı te da vi kı -la vuz la rın da be şin ci ba sa mak ta yük sek doz in ha ler kor ti kos te ro id (>800 µgr/gün), in ha ler uzun etki li β2 ago nist ve oral lö kot ri en re sep tör an ta go nist te da vi si ne rağ men as tı mı kon trol al tı na alı na ma yan ve se rum to tal IgE dü ze yi 30-700 IU/ml ara sın da olan, 12 ya şın dan bü yük, ağır per sistan al ler jik as tım lı has ta lar için öne ril mek te dir. Kli ni ği miz de, ağır per sis tan as tım ta nı sıy la iz le nen ve son üç ay lık dö nem de bi ri pno mo me di as ti num ile komp li ke iki ağır as tım ata ğı ge li şen ol gu muza oma li zu mab te da vi si baş lan dı. Ol gu muz, ül ke miz de ço cuk luk ça ğı as tım po pü las yo nun da bil diri len ilk oma li zu mab uy gu la ma sı olup, te da vi nin ilk yedi ay lık dö ne mi de ğer len di ril di ğin de te da vi ön ce si ne gö re gün lük as tım semp tom sko run da azal ma, ha yat ya şam ka li te sin de ve so lu num fonksi yon ...

show abstract

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Cited by 165 publications

References 17 publications

High-altitude treatment in atopic and nonatopic patients with severe asthma

High-altitude treatment in atopic and nonatopic patients with severe asthma

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report

Contact Info

Product

Resources

About